Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONQUER: Qapzola in NMIBC
NCT03224182Phase 3Terminated
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Aug 2017
- Primary completion
- Sep 2019
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of apaziquone in non-muscle-invasive bladder cancer (NMIBC), sponsored by Spectrum Pharmaceuticals, Inc.. Started Aug 2017; status: terminated.
02
Drugs
apaziquone
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03224182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03224182.